Limited patient data has also demonstrated clinical benefit of the KIT-targeted tyrosine kinase inhibitor toceranib in canine GIST suggesting shared oncogenic mechanisms and therapeutic sensitivities that may make canine GIST a useful model for the human tumor. This evidence concerns the gene KIT and gastrointestinal stromal tumor.